Concr Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Employees
  • 15

Employees

  • Latest Deal Type
  • Accelerator/​Inc

  • Investors
  • 19

Concr General Information

Description

Developer of a cloud-based therapeutic platform designed to improve cancer treatment through the prediction of patients' responses. The company's platform identifies optimal treatment for an individual, reduces treatment resistance, and offers patient-specific cancer progression and evidence-based personalized treatment plans, enabling users to proactively adapt treatment before it becomes ineffective.

Contact Information

Website
www.concr.co
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Regent House
  • 316a Beulah Hill
  • London SE19 3HF
  • England, United Kingdom
Primary Industry
Therapeutic Devices
Other Industries
Other Healthcare Technology Systems
Biotechnology
Corporate Office
  • Regent House
  • 316a Beulah Hill
  • London SE19 3HF
  • England, United Kingdom

Concr Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Concr Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Accelerator/Incubator 01-Jan-2025 Completed Generating Revenue
5. Later Stage VC 12-Aug-2024 Completed Generating Revenue
4. Seed Round 01-Nov-2023 Completed Generating Revenue
3. Seed Round 05-Oct-2022 Completed Generating Revenue
2. Accelerator/Incubator 24-Sep-2020 $13.1K $13.1K Completed Startup
1. Accelerator/Incubator 10-Dec-2019 Completed Startup
To view Concr’s complete valuation and funding history, request access »

Concr Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary
Ordinary
Ordinary
Ordinary 293,229 $0.000129 $2.19 $2.19 1x $2.19 11.28%
Ordinary 236,269 $0.000129 $1.33 $1.33 1x $1.33 9.09%
To view Concr’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Concr Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a cloud-based therapeutic platform designed to improve cancer treatment through the prediction of patients'
Therapeutic Devices
London, United Kingdom
15 As of 2024

Boston, MA
 

Cary, NC
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Concr Competitors (3)

One of Concr’s 3 competitors is Genialis, a Venture Capital-Backed company based in Boston, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Genialis Venture Capital-Backed Boston, MA
OncoHost Venture Capital-Backed Cary, NC
Cyted Health Venture Capital-Backed Cambridge, United Kingdom
You’re viewing 3 of 3 competitors. Get the full list »

Concr Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Concr Investors (19)

Investor Name Investor Type Holding Investor Since Participating Rounds
BioIndustry Association Accelerator/Incubator Minority
Blue Falcon Capital Venture Capital Minority
Cambridge Enterprise Ventures Venture Capital Minority
Debiopharm Innovation Fund Corporate Venture Capital Minority
Innovate UK Government Minority
You’re viewing 5 of 19 investors. Get the full list »

Concr FAQs

  • When was Concr founded?

    Concr was founded in 2018.

  • Where is Concr headquartered?

    Concr is headquartered in London, United Kingdom.

  • What is the size of Concr?

    Concr has 15 total employees.

  • What industry is Concr in?

    Concr’s primary industry is Therapeutic Devices.

  • Is Concr a private or public company?

    Concr is a Private company.

  • What is Concr’s current revenue?

    The current revenue for Concr is .

  • How much funding has Concr raised over time?

    Concr has raised $4.64M.

  • Who are Concr’s investors?

    BioIndustry Association, Blue Falcon Capital, Cambridge Enterprise Ventures, Debiopharm Innovation Fund, and Innovate UK are 5 of 19 investors who have invested in Concr.

  • Who are Concr’s competitors?

    Genialis, OncoHost, and Cyted Health are competitors of Concr.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process